Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Completes PMA Application For Symplicity Spyral Hypertension Device

Executive Summary

The six-month results from SPYRAL HTN ON MED trial of Medtronic’s Symplicity Spyral renal denervation system did not meet its primary endpoint, but the company and analysts expect the FDA will still approve Symplicity Spyral as the first renal denervation system available in the US to treat uncontrolled hypertension.

You may also be interested in...

Cardio Catch-Up: Medtronic, Recor, Pulnovo Report Progress On Denervation To Treat Hypertension

The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.

Finding A Future For Renal Denervation With Better Controlled Trials

Minimizing the variability in patient attributes and procedural techniques will be crucial to future renal denervation trials having a chance at success, experts suggested last month at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.

CMR Signs Deal With J&J To Bring Robots To Europe And South America

CMR Surgical will collaborate with Johnson & Johnson/Ethicon to expand access to its Versius robotic surgery system.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts